{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T02:42:55Z","timestamp":1761100975538},"reference-count":81,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2003,8,1]],"date-time":"2003-08-01T00:00:00Z","timestamp":1059696000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[2003,8]]},"DOI":"10.4065\/78.8.981","type":"journal-article","created":{"date-parts":[[2009,1,24]],"date-time":"2009-01-24T01:20:27Z","timestamp":1232760027000},"page":"981-990","source":"Crossref","is-referenced-by-count":3,"title":["Hematopoietic Cell Transplantation for Adult Patients With Myelodysplastic Syndromes and Myeloproliferative Disorders"],"prefix":"10.4065","volume":"78","author":[{"given":"Martin","family":"Benesch","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H. Joachim","family":"Deeg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.4065\/78.8.981_bib1","series-title":"Hematology: Basic Principles and Practice","first-page":"1106","article-title":"Myelodysplastic syndrome","author":"Greenberg","year":"2000"},{"key":"10.4065\/78.8.981_bib2","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1182\/blood.V74.1.395.395","article-title":"Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: a multivariate analysis of prognostic factors in 370 patients","volume":"74","author":"Sanz","year":"1989","journal-title":"Blood"},{"key":"10.4065\/78.8.981_bib3","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/j.1365-2141.1982.tb08475.x","article-title":"Proposals for the classification of the myelodysplastic syndromes","volume":"51","author":"Bennett","year":"1982","journal-title":"Br J Haematol"},{"key":"10.4065\/78.8.981_bib4","doi-asserted-by":"crossref","first-page":"3835","DOI":"10.1200\/JCO.1999.17.12.3835","article-title":"World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting\u2014Airlie House, Virginia, November 1997","volume":"17","author":"Harris","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.4065\/78.8.981_bib5","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1182\/blood.V89.6.2079","article-title":"International scoring system for evaluating prognosis in myelodysplastic syndromes [published correction appears in Blood. 1998;91:1100]","volume":"89","author":"Greenberg","year":"1997","journal-title":"Blood"},{"issue":"suppl 1","key":"10.4065\/78.8.981_bib6","first-page":"S25","article-title":"Allogeneic bone marrow transplantation for myelodysplastic syndrome: outcomes analysis according to IPSS score","volume":"12","author":"Appelbaum","year":"1998","journal-title":"Leukemia"},{"key":"10.4065\/78.8.981_bib7","first-page":"1997","article-title":"Bone marrow transplantation from HLA-identical siblings as treatment for myelodysplasia","volume":"100","author":"Sierra","year":"2002","journal-title":"Blood"},{"key":"10.4065\/78.8.981_bib8","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1182\/blood.V6.4.372.372","article-title":"Some speculations on the myeloproliferative syndromes [editorial]","volume":"6","author":"Dameshek","year":"1951","journal-title":"Blood"},{"key":"10.4065\/78.8.981_bib9","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1002\/1097-0142(19910515)67:10<2658::AID-CNCR2820671042>3.0.CO;2-C","article-title":"Life expectancy of patients with chronic nonleukemic myeloproliferative disorders","volume":"67","author":"Rozman","year":"1991","journal-title":"Cancer"},{"key":"10.4065\/78.8.981_bib10","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/j.1365-2141.1988.tb02507.x","article-title":"A prognostic classification of myelofibrosis with myeloid metaplasia","volume":"70","author":"Barosi","year":"1988","journal-title":"Br J Haematol"},{"key":"10.4065\/78.8.981_bib11","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1182\/blood.V88.3.1013.1013","article-title":"Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system","volume":"88","author":"Dupriez","year":"1996","journal-title":"Blood"},{"key":"10.4065\/78.8.981_bib12","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1182\/blood.V99.3.840","article-title":"Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients","volume":"99","author":"Onida","year":"2002","journal-title":"Blood"},{"key":"10.4065\/78.8.981_bib13","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1001\/jama.1994.03510250075039","article-title":"Users' guides to the medical literature, II: how to use an article about therapy or prevention. B. What were the results and will they help me in caring for my patients?","volume":"271","author":"Guyatt","year":"1994","journal-title":"JAMA"},{"issue":"4, suppl 7","key":"10.4065\/78.8.981_bib14","first-page":"95","article-title":"Bone marrow transplantation: a review","volume":"36","author":"Thomas","year":"1999","journal-title":"Semin Hematol"},{"issue":"11, pt 1","key":"10.4065\/78.8.981_bib15","first-page":"74a","article-title":"A decision analysis of allogeneic stem cell transplantation for MDS: delayed transplantation for low risk MDS is associated with improved outcome [abstract]","volume":"100","author":"Cutler","year":"2002","journal-title":"Blood"},{"key":"10.4065\/78.8.981_bib16","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1182\/blood.V98.8.2326","article-title":"Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes (MDSs) and acute myeloid leukemia following MDS [published correction appears in Blood. 2002;99:1535]","volume":"98","author":"de Witte","year":"2001","journal-title":"Blood"},{"key":"10.4065\/78.8.981_bib17","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/j.1365-2141.1990.tb02558.x","article-title":"Allogeneic bone marrow transplantation for secondary leukaemia and myelodysplastic syndrome: a survey by the Leukaemia Working Party of the European Bone Marrow Transplantation Group (EBMTG)","volume":"74","author":"De Witte","year":"1990","journal-title":"Br J Haematol"},{"key":"10.4065\/78.8.981_bib18","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1200\/JCO.1990.8.10.1707","article-title":"Bone marrow transplantation for myelodysplasia and secondary acute nonlymphoblastic leukemia","volume":"8","author":"Longmore","year":"1990","journal-title":"J Clin Oncol"},{"key":"10.4065\/78.8.981_bib19","doi-asserted-by":"crossref","first-page":"590","DOI":"10.7326\/0003-4819-112-8-590","article-title":"Bone marrow transplantation for patients with myelodysplasia: pretreatment variables and outcome","volume":"112","author":"Appelbaum","year":"1990","journal-title":"Ann Intern Med"},{"key":"10.4065\/78.8.981_bib20","first-page":"445","article-title":"Treatment of myelodysplastic syndrome with busulfan-cyclophosphamide conditioning followed by allogeneic BMT","volume":"10","author":"Nevill","year":"1992","journal-title":"Bone Marrow Transplant"},{"key":"10.4065\/78.8.981_bib21","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1182\/blood.V81.8.2194.2194","article-title":"Busulfan-based regimens and allogeneic bone marrow transplantation in patients with myelodysplastic syndromes","volume":"81","author":"Ratanatharathorn","year":"1993","journal-title":"Blood"},{"key":"10.4065\/78.8.981_bib22","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1182\/blood.V82.2.677.677","article-title":"Allogeneic bone marrow transplantation for 93 patients with myelodysplastic syndrome","volume":"82","author":"Anderson","year":"1993","journal-title":"Blood"},{"key":"10.4065\/78.8.981_bib23","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.1200\/JCO.1995.13.12.2973","article-title":"Busulfan\/cyclophosphamide as conditioning regimen for allogeneic bone marrow transplantation for myelodysplasia","volume":"13","author":"O'Donnell","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.4065\/78.8.981_bib24","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1200\/JCO.1996.14.1.220","article-title":"Allogeneic marrow transplantation for myelodysplastic syndrome with advanced disease morphology: a phase II study of busulfan, cyclophosphamide, and total-body irradiation and analysis of prognostic factors","volume":"14","author":"Anderson","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.4065\/78.8.981_bib25","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1182\/blood.V87.1.51.51","article-title":"Allogeneic marrow transplantation for refractory anemia: a comparison of two preparative regimens and analysis of prognostic factors","volume":"87","author":"Anderson","year":"1996","journal-title":"Blood"},{"key":"10.4065\/78.8.981_bib26","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1046\/j.1365-2141.1996.4811022.x","article-title":"Unrelated donor marrow transplantation for myelodysplasia (MDS) and MDS-related acute myeloid leukaemia","volume":"93","author":"Anderson","year":"1996","journal-title":"Br J Haematol"},{"key":"10.4065\/78.8.981_bib27","first-page":"745","article-title":"Treatment of patients with myelodysplastic syndromes with allogeneic bone marrow transplantation from genotypically HLA-identical sibling and alternative donors","volume":"17","author":"Demuynck","year":"1996","journal-title":"Bone Marrow Transplant"},{"key":"10.4065\/78.8.981_bib28","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1182\/blood.V88.1.358.358","article-title":"Factors influencing outcome in de novo myelodysplastic syndromes treated by allogeneic bone marrow transplantation: a long-term study of 71 patients","volume":"88","author":"Sutton","year":"1996","journal-title":"Blood"},{"key":"10.4065\/78.8.981_bib29","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1038\/sj.bmt.1700739","article-title":"Outcome of allogeneic bone marrow transplantation with lymphocyte-depleted marrow grafts in adult patients with myelodysplastic syndromes","volume":"19","author":"Mattijssen","year":"1997","journal-title":"Bone Marrow Transplant"},{"key":"10.4065\/78.8.981_bib30","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1182\/blood.V92.6.1910","article-title":"Cytogenetic abnormalities in primary myelodysplastic syndrome are highly predictive of outcome after allogeneic bone marrow transplantation","volume":"92","author":"Nevill","year":"1998","journal-title":"Blood"},{"key":"10.4065\/78.8.981_bib31","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/sj.bmt.1701084","article-title":"Bone marrow transplantation from HLA-identical siblings as first-line treatment in patients with myelodysplastic syndromes: early transplantation is associated with improved outcome","volume":"21","author":"Runde","year":"1998","journal-title":"Bone Marrow Transplant"},{"key":"10.4065\/78.8.981_bib32","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1038\/sj.bmt.1701269","article-title":"Unrelated bone marrow transplantation in patients with myelodysplastic syndromes and secondary acute myeloid leukemia: an EBMT survey","volume":"21","author":"Arnold","year":"1998","journal-title":"Bone Marrow Transplant"},{"key":"10.4065\/78.8.981_bib33","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1046\/j.1365-2141.1999.01205.x","article-title":"Treatment of advanced myelodysplastic syndrome with a regimen including recombinant human granulocyte colony-stimulating factor preceding allogeneic bone marrow transplantation","volume":"104","author":"Okamoto","year":"1999","journal-title":"Br J Haematol"},{"key":"10.4065\/78.8.981_bib34","first-page":"157","article-title":"Allogeneic stem cell transplantation for patients with high-risk myelodysplastic syndrome","volume":"98","author":"Hsu","year":"1999","journal-title":"J Formos Med Assoc"},{"key":"10.4065\/78.8.981_bib35","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1182\/blood.V95.4.1188.004k38_1188_1194","article-title":"Allogeneic and syngeneic marrow transplantation for myelodysplastic syndrome in patients 55 to 66 years of age","volume":"95","author":"Deeg","year":"2000","journal-title":"Blood"},{"key":"10.4065\/78.8.981_bib36","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1038\/sj.bmt.1702432","article-title":"Analysis of prognostic factors for allogeneic marrow transplantation following busulfan and cyclophosphamide in myelodysplastic syndrome and after leukemic transformation","volume":"25","author":"Copelan","year":"2000","journal-title":"Bone Marrow Transplant"},{"key":"10.4065\/78.8.981_bib37","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1046\/j.1365-2141.2000.02200.x","article-title":"Haematopoietic stem cell transplantation for patients with myelodysplastic syndromes and secondary acute myeloid leukaemias: a report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT)","volume":"110","author":"de Witte","year":"2000","journal-title":"Br J Haematol"},{"key":"10.4065\/78.8.981_bib38","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1053\/bbmt.2001.v7.pm11302550","article-title":"Relapse after allogeneic bone marrow transplantation for refractory anemia is increased by shielding lungs and liver during total body irradiation","volume":"7","author":"Anderson","year":"2001","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.4065\/78.8.981_bib39","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/ajh.1121","article-title":"Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced myelodysplastic syndrome and acute myelogenous leukemia","volume":"67","author":"Bibawi","year":"2001","journal-title":"Am J Hematol"},{"key":"10.4065\/78.8.981_bib40","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1038\/sj.leu.2402296","article-title":"Genotypically nonidentical related donors for transplantation of patients with myelodysplastic syndromes: comparison with unrelated donor transplantation and autologous stem cell transplantation","volume":"15","author":"de Witte","year":"2001","journal-title":"Leukemia"},{"key":"10.4065\/78.8.981_bib41","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1182\/blood.V99.6.1943","article-title":"Unrelated donor marrow transplantation for myelodysplastic syndromes: outcome analysis in 510 transplants facilitated by the National Marrow Donor Program","volume":"99","author":"Castro-Malaspina","year":"2002","journal-title":"Blood"},{"key":"10.4065\/78.8.981_bib42","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1182\/blood-2002-02-0527","article-title":"Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome","volume":"100","author":"Deeg","year":"2002","journal-title":"Blood"},{"key":"10.4065\/78.8.981_bib43","doi-asserted-by":"crossref","first-page":"4370","DOI":"10.1182\/blood.V99.12.4370","article-title":"Retrospective comparison of bone marrow and granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells for allogeneic stem cell transplantation using HLA identical sibling donors in myelodysplastic syndromes","volume":"99","author":"Guardiola","year":"2002","journal-title":"Blood"},{"key":"10.4065\/78.8.981_bib44","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1053\/bbmt.2002.v8.pm11939606","article-title":"Hematopoietic stem cell transplantation for advanced myelodysplastic syndrome after conditioning with busulfan and fractionated total body irradiation is associated with low relapse rate but considerable nonrelapse mortality","volume":"8","author":"Jurado","year":"2002","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.4065\/78.8.981_bib45","first-page":"743","article-title":"Allogeneic bone marrow transplantation for primary myelofibrosis","volume":"16","author":"Singhal","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"10.4065\/78.8.981_bib46","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1046\/j.1365-2141.1997.3073124.x","article-title":"Allogeneic bone marrow transplantation for agnogenic myeloid metaplasia","volume":"98","author":"Guardiola","year":"1997","journal-title":"Br J Haematol"},{"key":"10.4065\/78.8.981_bib47","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1046\/j.1365-2141.1997.3083125.x","article-title":"Allogeneic marrow transplantation for primary myelofibrosis and myelofibrosis secondary to polycythaemia vera or essential thrombocytosis","volume":"98","author":"Anderson","year":"1997","journal-title":"Br J Haematol"},{"key":"10.4065\/78.8.981_bib48","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1002\/(SICI)1096-8652(199801)57:1<24::AID-AJH4>3.0.CO;2-3","article-title":"Allogeneic marrow transplantation for myeloproliferative disor-ders other than chronic myelogenous leukemia: review of forty cases","volume":"57","author":"Przepiorka","year":"1998","journal-title":"Am J Hematol"},{"key":"10.4065\/78.8.981_bib49","first-page":"2831","volume":"93","author":"Guardiola","year":"1999","journal-title":"Blood"},{"key":"10.4065\/78.8.981_bib50","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1046\/j.1365-2141.2001.02584.x","article-title":"Haemopoietic stem cell transplantation for advanced polycythaemia vera or essential thrombocythaemia","volume":"112","author":"Jurado","year":"2001","journal-title":"Br J Haematol"},{"key":"10.4065\/78.8.981_bib51","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1080\/1042819022386626","article-title":"Curative therapy of advanced essential thrombocythemia or polycythemia vera by hemopoietic stem cell transplantation","volume":"43","author":"Platzbecker","year":"2002","journal-title":"Leuk Lymphoma"},{"key":"10.4065\/78.8.981_bib52","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1046\/j.1365-2141.2000.02133.x","article-title":"Treatment of chronic myelomonocytic leukaemia by allogeneic marrow transplantation","volume":"110","author":"Zang","year":"2000","journal-title":"Br J Haematol"},{"key":"10.4065\/78.8.981_bib53","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1046\/j.1365-2141.2002.03552.x","article-title":"Allogeneic stem cell transplantation of adult chronic myelomonocytic leukaemia: a report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT)","volume":"118","author":"Kr\u00f6ger","year":"2002","journal-title":"Br J Haematol"},{"key":"10.4065\/78.8.981_bib54","first-page":"3853","article-title":"Autologous bone marrow transplantation for patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia following MDS","volume":"90","author":"De Witte","year":"1997","journal-title":"Blood"},{"key":"10.4065\/78.8.981_bib55","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/sj.leu.2401387","article-title":"A prospective study of autologous bone marrow or peripheral blood stem cell transplantation after intensive chemotherapy in myelodysplastic syndromes","volume":"13","author":"Wattel","year":"1999","journal-title":"Leukemia"},{"key":"10.4065\/78.8.981_bib56","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1182\/blood.V98.3.586","article-title":"Myeloablation and autologous peripheral blood stem cell rescue results in hematologic and clinical responses in patients with myeloid metaplasia with myelofibrosis","volume":"98","author":"Anderson","year":"2001","journal-title":"Blood"},{"key":"10.4065\/78.8.981_bib57","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/sj.bmt.1702204","article-title":"Miniallografts: ongoing trials in humans [editorial]","volume":"25","author":"Carella","year":"2000","journal-title":"Bone Marrow Transplant"},{"key":"10.4065\/78.8.981_bib58","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/sj.bmt.1703215","article-title":"A fludarabine-based dose-reduced conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors in patients with myelodysplastic syndrome","volume":"28","author":"Kr\u00f6ger","year":"2001","journal-title":"Bone Marrow Transplant"},{"key":"10.4065\/78.8.981_bib59","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1182\/blood-2002-02-0400","article-title":"Evidence for a graft-versus-leukemia effect after allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning in acute myelogenous leukemia and myelodysplastic syndromes","volume":"100","author":"Martino","year":"2002","journal-title":"Blood"},{"key":"10.4065\/78.8.981_bib60","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1046\/j.1365-2141.2002.03796.x","article-title":"Allogeneic stem cell transplantation in the myelodysplastic syndromes: interim results of outcome following reduced-intensity conditioning compared with standard preparative regimens","volume":"119","author":"Parker","year":"2002","journal-title":"Br J Haematol"},{"key":"10.4065\/78.8.981_bib61","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1046\/j.1365-2141.2000.02123.x","article-title":"Reduced intensity thiotepa-cyclophosphamide conditioning for allogeneic haemopoietic stem cell transplants (HSCT) in patients up to 60 years of age","volume":"109","author":"Raiola","year":"2000","journal-title":"Br J Haematol"},{"key":"10.4065\/78.8.981_bib62","doi-asserted-by":"crossref","first-page":"3340","DOI":"10.1200\/JCO.2001.19.14.3340","article-title":"Allogeneic hematopoietic stem-cell transplantation after nonmyeloablative preparative regimens: impact of pretransplantation and posttransplantation factors on outcome","volume":"19","author":"Michallet","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.4065\/78.8.981_bib63","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1182\/blood.V99.6.2255","article-title":"Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia","volume":"99","author":"Devine","year":"2002","journal-title":"Blood"},{"key":"10.4065\/78.8.981_bib64","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1038\/sj.bmt.1701781","article-title":"Myelodysplasia and acute leukemia following high-dose chemotherapy and autologous bone marrow or peripheral blood stem cell transplantation","volume":"23","author":"Sobecks","year":"1999","journal-title":"Bone Marrow Transplant"},{"key":"10.4065\/78.8.981_bib65","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1200\/JCO.1998.16.3.1008","article-title":"Secondary myelodysplasia and acute leukemia in breast cancer patients after autologous bone marrow transplant","volume":"16","author":"Laughlin","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.4065\/78.8.981_bib66","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1200\/JCO.1999.17.10.3128","article-title":"Outcome in patients with myelodysplastic syndrome after autologous bone marrow transplantation for non-Hodgkin's lymphoma","volume":"17","author":"Friedberg","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.4065\/78.8.981_bib67","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1182\/blood.V89.7.2578","article-title":"Stem cell transplantation for secondary acute myeloid leukemia: evaluation of transplantation as initial therapy or following induction chemotherapy","volume":"89","author":"Anderson","year":"1997","journal-title":"Blood"},{"key":"10.4065\/78.8.981_bib68","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1200\/JCO.2000.18.5.963","article-title":"Allogeneic bone marrow transplantation for therapy-related myelodsyplastic syndrome and acute myeloid leukemia: a long-term study of 70 patients: report of the French Society of Bone Marrow Transplantation","volume":"18","author":"Yakoub-Agha","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.4065\/78.8.981_bib69","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1200\/JCO.2001.19.8.2134","article-title":"Hematopoietic stem-cell transplantation for treatment-related leukemia or myelodysplasia","volume":"19","author":"Witherspoon","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.4065\/78.8.981_bib70","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1038\/sj.bmt.1700971","article-title":"Bone marrow transplantation for therapy-related myelodysplasia: comparison with primary myelodysplasia","volume":"20","author":"Ballen","year":"1997","journal-title":"Bone Marrow Transplant"},{"key":"10.4065\/78.8.981_bib71","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1007\/s002770000258","article-title":"Treatment of relapsing leukemia after allogeneic blood stem cell transplantation by using dose-reduced conditioning followed by donor blood stem cells and GM-CSF","volume":"80","author":"Platzbecker","year":"2001","journal-title":"Ann Hematol"},{"key":"10.4065\/78.8.981_bib72","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1046\/j.1365-2141.2001.03150.x","article-title":"Treatment of relapse after allogeneic bone marrow transplantation with reduced intensity conditioning (FLAG \u00b1 Ida) and second allogeneic stem cell transplant","volume":"115","author":"Pawson","year":"2001","journal-title":"Br J Haematol"},{"key":"10.4065\/78.8.981_bib73","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1182\/blood.V86.5.2041.bloodjournal8652041","article-title":"Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients","volume":"86","author":"Kolb","year":"1995","journal-title":"Blood"},{"key":"10.4065\/78.8.981_bib74","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1182\/blood.V87.6.2195.bloodjournal8762195","article-title":"Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation","volume":"87","author":"Slavin","year":"1996","journal-title":"Blood"},{"key":"10.4065\/78.8.981_bib75","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/sj.bmt.1702596","article-title":"Donor leukocyte infusion for Japanese patients with relapsed leukemia after allogeneic bone marrow transplantation: lower incidence of acute graft-versus-host disease and improved outcome","volume":"26","author":"Shiobara","year":"2000","journal-title":"Bone Marrow Transplant"},{"key":"10.4065\/78.8.981_bib76","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1200\/JCO.20.2.405","article-title":"Prospective trial of chemotherapy and donor leukocyte infusions for relapse of advanced myeloid malignancies after allogeneic stem-cell transplantation","volume":"20","author":"Levine","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.4065\/78.8.981_bib77","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1200\/JCO.1997.15.2.433","article-title":"Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation","volume":"15","author":"Collins","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.4065\/78.8.981_bib78","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S0145-2126(00)00049-7","article-title":"Hematopoietic stem cell transplantation in patients with myelodysplastic syndrome","volume":"24","author":"Deeg","year":"2000","journal-title":"Leuk Res"},{"issue":"11, pt 1","key":"10.4065\/78.8.981_bib79","first-page":"97a","article-title":"Prognostic significance of pretransplant multidimensional flow cytometric parameters for posttransplant survival and relapse in 111 patients with myelodysplastic syndrome (MDS) [abstract]","volume":"100","author":"Benesch","year":"2002","journal-title":"Blood"},{"issue":"11, pt 1","key":"10.4065\/78.8.981_bib80","first-page":"76a","article-title":"Nonmyeloablative hematopoietic stem cell transplants (NM-HSCT) using 10 HLA antigen matched unrelated donors (URDs) for patients (pts) with advanced hematologic malignancies [abstract]","volume":"100","author":"Maris","year":"2002","journal-title":"Blood"},{"issue":"11, pt 1","key":"10.4065\/78.8.981_bib81","first-page":"213a","article-title":"Conditioning with fludarabine and targeted busulfan before transplantation of allogeneic hematopoietic stem cells [abstract]","volume":"100","author":"Bornhaeuser","year":"2002","journal-title":"Blood"}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619611631455?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619611631455?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,15]],"date-time":"2020-05-15T01:13:07Z","timestamp":1589505187000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025619611631455"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,8]]},"references-count":81,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2003,8]]}},"alternative-id":["S0025619611631455"],"URL":"https:\/\/doi.org\/10.4065\/78.8.981","relation":{},"ISSN":["0025-6196"],"issn-type":[{"value":"0025-6196","type":"print"}],"subject":[],"published":{"date-parts":[[2003,8]]}}}